Managing Skin Irritation on AndroGel (testosterone topical): The HealthRX.com Step-by-Step Protocol

HealthRX.com

Rotate sites and let AndroGel dry before dressing

Print or save as PDF

From the public record

FDA adverse event reports naming application site skin reactions and testosterone

Through 2026-10-28, FDA had received 1,109 adverse event reports for testosterone that name application site skin reactions, out of 41,579 reports for the drug in all. 36 of these reports concerned female patients and 1,047 male patients.

FDA adverse event reports naming application site skin reactions and testosterone: the figures
MeasureValueNote
Reports naming application site skin reactions1,109
All reports for testosterone41,579
Share of this drug's reports naming it2.7%share of reports received, not of people taking the drug
Of those: female patients36reflects who takes the drug and who files reports
Of those: male patients1,047
Of those: sex not recorded26

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, data as of Oct 28, 2026

How this was calculated

Counted FAERS reports listing this active substance and at least one of these reaction terms: application site irritation, application site erythema, application site pruritus, application site rash. A report can name several reactions and several drugs. Counts by year use the date FDA received the report.

Scope: Reports with testosterone as a single-ingredient active substance (any brand), 4 MedDRA terms for application site skin reactions

FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs.

Download the data (CSV)

From the public record

Most reported events in FDA adverse event reports for testosterone

Through 2026-10-28, FDA had received 41,579 adverse event reports for testosterone, 22,742 of them marked serious by the reporter. The symptom terms named most often were myocardial infarction (3,478), deep vein thrombosis (2,297) and cerebrovascular accident (2,266).

Most reported events in FDA adverse event reports for testosterone: the figures
MeasureValueNote
All reports received41,579
Reports the reporter marked serious22,742death, hospitalisation, disability or similar outcome
Myocardial infarction3,478 reports
Deep vein thrombosis2,297 reports
Cerebrovascular accident2,266 reports
Pain2,229 reports
Pulmonary embolism2,141 reports

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, data as of Oct 28, 2026

How this was calculated

Counted FAERS reports listing this active substance, then the reaction terms named most often. A report can name several reactions, and a term can describe the illness being treated and not an effect of the drug. Terms about product use or complaints rather than symptoms (for example drug ineffective) were left out of the list.

Scope: Reports where FDA recorded testosterone as a single-ingredient active substance (any brand, not only AndroGel), all years to 2026-10-28

FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs.

Download the data (CSV)

From the public record

FDA label facts for testosterone

The FDA label read for testosterone (Natesto nasal gel, application NDA205488) was last revised on 2025-07-22. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.

FDA label facts for testosterone: the figures
MeasureValueNote
Label revision date2025-07-22
Label readNatesto nasal gelNDA205488, brand-name application
Boxed warningNo
Pregnancy sectionPresent
Lactation sectionPresent
Pediatric use sectionPresent
Geriatric use sectionPresent

Source: FDA drug label via openFDA, viewable on NIH DailyMed, data as of Nov 11, 2026

How this was calculated

Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.

Scope: One label: the newest prescription label for single-ingredient testosterone from an original manufacturer, not specific to AndroGel

Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.

Download the data (CSV)

At a glance

  • Incidence: Application-site reactions reported in approximately 3 to 5 percent of patients in the key AndroGel 1% registration trials, per the FDA-approved AndroGel prescribing information
  • Typical onset: Within the first 2 to 4 weeks of therapy; most reactions peak in week 1 before skin adapts
  • Mechanism: High-concentration ethanol (67% w/w in the 1% formulation) strips the stratum corneum lipid barrier, increasing transepidermal water loss and sensitizing keratinocytes to prolonged testosterone-gel contact
  • First-line management: Site rotation, full drying before clothing contact, low-potency topical corticosteroid for acute flares
  • Escalation trigger: No improvement after 2 weeks of first-line measures, or reaction spreads beyond the application site
  • Discontinuation trigger: Grade 3 or Grade 4 NCI CTCAE dermatitis, systemic hypersensitivity signs, or documented contact allergy to excipients confirmed by patch testing

Why AndroGel Causes Skin Irritation

Understanding the mechanism helps patients and prescribers choose the right intervention at each step. AndroGel 1% contains approximately 67% ethanol by weight as its primary solubilizing vehicle, and AndroGel 1.62% contains a similar alcohol load. Ethanol at these concentrations disrupts the intercellular lipid lamellae of the stratum corneum, reducing its barrier function and allowing residual testosterone and excipients to penetrate into the viable epidermis at higher-than-intended concentrations. The National Institutes of Health bookshelf chapter on transdermal drug delivery describes this barrier disruption as a predictable consequence of penetration-enhancing vehicles rather than a true allergic phenomenon in most cases.

The result is a spectrum of irritant contact dermatitis (ICD) rather than allergic contact dermatitis (ACD) in the majority of affected patients, a distinction that matters clinically because ICD is dose- and exposure-duration-dependent and responds to barrier repair, while ACD requires allergen avoidance and may necessitate formulation change. A 2019 review in Contact Dermatitis confirmed that ethanol-based topical vehicles are among the most common causes of ICD at application sites across dermatologic and endocrine preparations.

Secondary factors that worsen irritation include applying gel to freshly shaved skin (removes the stratum corneum surface layer), applying over broken or sunburned skin, occluding the site with tight clothing before the ethanol evaporates fully, and applying to skin already exposed to other alcohol-based products.

Step 1: Grade the Reaction Before Doing Anything Else

Skipping formal grading leads to under-treatment of serious reactions and over-treatment of mild ones. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 dermatitis grading system provides a reproducible framework:

  • Grade 1: Faint erythema, dry desquamation, no symptoms beyond mild pruritus. No functional limitation.
  • Grade 2: Moderate erythema, patchy moist desquamation, moderate pruritus. Patient reports noticeable discomfort but no limitation of activities of daily living.
  • Grade 3: Confluent moist desquamation, severe erythema, significant edema, bleeding on minor trauma, severe pruritus. Limits self-care ADLs.
  • Grade 4: Life-threatening consequences, skin necrosis, full-thickness dermal ulceration, or systemic hypersensitivity.

Photograph the site at baseline and at each follow-up appointment. This creates an objective record that prevents both premature escalation and inappropriate watchful waiting when a reaction is worsening.

Before assigning a grade, also confirm the reaction is actually at the application site. Reactions involving the face, genitals, or a sexual partner's skin suggest transfer rather than direct irritation and require a different management pathway covered in the AndroGel transfer risk page.

Step 2: First-Line Measures (Grade 1 and Grade 2)

These interventions address the mechanism directly. Apply all of them simultaneously rather than sequentially; waiting four weeks per intervention before adding the next one delays resolution unnecessarily.

Site rotation. The AndroGel prescribing information recommends application to the right and left upper arms, shoulders, or abdomen. Rotating among all approved sites on a fixed schedule (for example, left shoulder Monday, right shoulder Tuesday, abdomen Wednesday, and so on) reduces cumulative ethanol exposure at any single skin area. Patients often skip rotation and apply to the same spot daily out of habit. That habit is the single most correctable driver of application-site ICD.

Full drying before clothing contact. AndroGel requires a minimum of 5 minutes drying time per the prescribing information. A 2014 pharmacokinetic study published in Clinical Pharmacokinetics found that occlusion by clothing before complete evaporation increases skin surface concentration of both ethanol and testosterone significantly, worsening barrier disruption. Instruct patients to set a timer, not to rely on touch-drying, because the skin can feel dry before ethanol has fully evaporated.

Barrier repair between applications. Applying a fragrance-free ceramide-containing emollient (such as CeraVe Moisturizing Cream or Vanicream) to the application site 30 to 60 minutes before gel application, or immediately after the site has dried completely, replenishes stratum corneum lipids. The Journal of the American Academy of Dermatology published a 2016 review confirming that ceramide-dominant barrier repair formulations reduce ethanol-induced ICD severity scores significantly compared to petrolatum or no treatment.

Low-potency topical corticosteroid for active flares. A twice-daily application of 1% hydrocortisone cream to the irritated site for 5 to 7 days reduces acute inflammation without meaningful suppression of the hypothalamic-pituitary-gonadal axis at these topical doses. The American Academy of Dermatology contact dermatitis guidelines support low-potency corticosteroids as first-line treatment for mild-to-moderate ICD. Do not apply the corticosteroid and then apply AndroGel to the same site in the same application window; separate them by the full drying period.

Success at Step 2 looks like: Grade 1 reaction resolves within 7 to 10 days. Grade 2 reaction downgraded to Grade 1 within 2 weeks, with full resolution by week 4.

Failure at Step 2 looks like: No improvement or worsening after 2 weeks of all four measures applied correctly. Document this in the chart and move to Step 3.

What people on Reddit report

Accounts from people using testosterone gel who describe how they rotate application spots, let the gel dry, and what their doctors told them about these habits.

Humble_Practice6701 · Menopause

My doctor suggested different spots on my upper arms, and was very specific about rotating the spots each night. It doesn't work properly if you repeatedly use the same spot. I also use the backs of my knees.

Reports that their doctor specified rotating application spots nightly and warned against reusing the same spot.

Read the source discussion

Giraffe-gurl · Menopause

My doctor told me to rotate the location, too. Said it's for irritation and hair growth. She said you can start growing little patches of hair (if the testosterone is high enough). She said the dose is usually too low to really cause hair growth, but if you keep placing it in the same place, it could cause issues.

Says their doctor advised rotating the spot to avoid irritation and problems from repeated placement in one area.

Read the source discussion

shortifiable · Menopause

When asked about rotating, he was told that he could if he wanted to but it wasn't necessary, plus inner thighs are usually covered so the risk of transfer to others was minimal.

Describes a clinician saying rotation was optional and that covered sites reduce transfer risk, which differs from other accounts.

Read the source discussion

W1nd0wPane · TestosteroneKickoff

You do have to be careful to thoroughly wash your hands after applying it, let it dry for 5 minutes and then be sure to put a shirt on over it and be conscious about not rubbing that area on other people or pets.

Describes waiting for the gel to dry before covering the site with clothing and avoiding contact with others.

Read the source discussion

0-60_now_what · TestosteroneKickoff

First off, 3 hours to absorb is not the same as the time it takes to dry. The manufacturer says no swimming or showering for 5 hours, so I suspect after that it is completely absorbed.

Explains that drying time and full absorption time differ, based on the manufacturer's bathing guidance.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Step 3: Escalation Measures (Grade 2 Persistent, Grade 3)

Patch testing for contact allergy. When a Grade 2 reaction persists despite Step 2 measures, or when a Grade 3 reaction occurs at any point, refer for patch testing. ACD to AndroGel excipients (including carbomer 980 and isopropyl myristate) has been documented in the literature. A case series in Contact Dermatitis (2016) identified testosterone propionate and isopropyl myristate as patch-test positive in a subset of TRT users presenting with persistent application-site dermatitis. Distinguishing ACD from ICD changes the management completely: ICD responds to barrier modification, while ACD requires switching to a formulation that does not contain the offending allergen.

Formulation switch within topical TRT. If patch testing identifies no specific allergen but ICD persists, consider switching from AndroGel 1% (67% ethanol) to AndroGel 1.62% (the higher-concentration formulation allows a smaller volume per dose, reducing total ethanol applied per application). Published comparative data in The Journal of Clinical Endocrinology and Metabolism show that AndroGel 1.62% achieves comparable serum testosterone levels with approximately 30% less gel volume applied, which translates to proportionally less ethanol exposure per application.

Formulation switch to non-alcohol TRT. If both AndroGel formulations produce unacceptable ICD, the evidence base supports switching to testosterone solution 2% (Axiron, applied to the axilla, lower alcohol load per site), testosterone gel 2% (Fortesta, applied to the thigh, different vehicle composition), or intramuscular/subcutaneous testosterone if topical therapy is not tolerated. The Endocrine Society clinical practice guideline on male hypogonadism notes that formulation choice should be individualized based on tolerability, and that persistent application-site reactions are an acceptable clinical reason to switch delivery route.

Medium-potency topical corticosteroid for Grade 3. Grade 3 ICD with confluent moist desquamation may require a short course of triamcinolone 0.1% for 5 to 7 days under dermatology supervision. The AAD contact dermatitis guidelines support escalation to mid-potency agents when low-potency corticosteroids fail, with close monitoring for skin atrophy if application sites overlap with the AndroGel site.

Step 4: Discontinuation Criteria

Stop AndroGel and do not rechallenge with any topical testosterone formulation under the following conditions:

  • Grade 3 or Grade 4 dermatitis that does not improve within 48 to 72 hours of stopping the gel, suggesting a component of ACD with ongoing systemic immune involvement.
  • Confirmed patch-test positive ACD to testosterone itself (not just an excipient), since all topical testosterone formulations will contain the same allergen.
  • Any signs of systemic hypersensitivity: urticaria beyond the application site, angioedema, bronchospasm, or anaphylaxis. These require immediate emergency evaluation per FDA MedWatch adverse event reporting guidelines.
  • Patient preference after documented failure of Steps 1 through 3. Patient-reported quality of life is a legitimate discontinuation reason in elective therapy.

After stopping AndroGel, most application-site ICD resolves within 7 to 14 days without further treatment. Document the reaction severity, the excipients involved if patch tested, and the clinical course in the patient's allergy record to inform future prescribing of any alcohol-vehicle topical medication.

Monitoring Timeline Summary

TimepointWhat to AssessAction if Worse
Day 7Grade change from baselineAdd barrier emollient if not already using
Day 14Grade change, adherence to rotation and dryingMove to Step 3 escalation
Week 4Skin fully clear or residual grade 1Maintain Step 2 measures
Week 6-8If still Grade 2 or higherPatch test, formulation switch
Any timeGrade 3 or Grade 4Immediate Step 3 or Step 4

Frequently asked questions

How common is skin irritation with AndroGel?

The FDA-approved AndroGel prescribing information reports application-site reactions in approximately 3 to 5 percent of patients in registration trials. Mild transient dryness or faint redness during the first week is more common than that and often resolves without any intervention as skin adapts to the ethanol vehicle.

Can I apply moisturizer to prevent irritation before putting on AndroGel?

Yes, with timing. Apply a ceramide-containing, fragrance-free emollient 30 to 60 minutes before AndroGel, allowing it to absorb fully first. Applying immediately before the gel may affect testosterone absorption by altering the stratum corneum permeability. The Journal of the American Academy of Dermatology barrier repair review supports pre-application barrier repair for ethanol-vehicle ICD.

Is the skin irritation an allergy to testosterone or to the gel base?

Most reactions are irritant contact dermatitis from the ethanol vehicle, not allergy. True allergic contact dermatitis to testosterone or excipients like isopropyl myristate is less common but documented. Patch testing distinguishes the two. A 2016 Contact Dermatitis case series found excipient sensitivity in a meaningful proportion of persistent cases.

What does Grade 3 skin irritation look like and when should I go to the doctor?

Grade 3 by NCI CTCAE v5.0 criteria means confluent moist desquamation, significant swelling, bleeding on minor contact, or severe pain at the application site. See a provider within 24 to 48 hours if you develop any of these findings. Do not apply more gel until assessed.

Will rotating application sites actually make a difference?

Yes. Daily application to the same site means daily ethanol exposure to the same stratum corneum before it has repaired itself. Rotation gives skin 48 to 72 hours of recovery time between exposures. The AndroGel prescribing information recommends rotation explicitly for this reason.

Can I use hydrocortisone cream every day long-term to control the irritation?

No. Using 1% hydrocortisone cream continuously on the same site risks skin atrophy, striae, and telangiectasia over weeks to months. Short courses of 5 to 7 days for acute flares are appropriate. If you need hydrocortisone more than twice a month at the same site, that is an escalation trigger warranting a clinical review. The AAD contact dermatitis guidelines address long-term corticosteroid risks on thin-skin application sites.

Is AndroGel 1.62% less irritating than AndroGel 1%?

Potentially, because the higher-concentration formulation requires a smaller applied volume to deliver the same testosterone dose, meaning less total ethanol per application. A comparative pharmacokinetic study in JCEM documented approximately 30% lower gel volume needed with the 1.62% formulation, which in practice reduces ethanol load per application.

What are the alternative TRT options if AndroGel keeps irritating my skin?

The Endocrine Society hypogonadism guideline lists several alternatives: testosterone solution 2% (axillary application, different vehicle), Fortesta gel 2% (thigh application), testosterone patches (different vehicle but their own skin risk), intramuscular testosterone cypionate or enanthate, subcutaneous pellets, or oral testosterone undecanoate. Each has its own tolerability and adherence profile.

How long does skin irritation last after stopping AndroGel?

For irritant contact dermatitis, most application-site reactions resolve within 7 to 14 days after stopping the gel, as the stratum corneum repairs itself. Allergic contact dermatitis can persist longer, sometimes 3 to 4 weeks, and may require topical corticosteroid treatment during resolution. The NIH transdermal drug delivery reference explains the barrier repair timeline in detail.

Should I report a severe skin reaction from AndroGel to the FDA?

Yes. Serious or unexpected adverse reactions from any prescription medication can be reported through the FDA MedWatch program. Your prescriber can also file on your behalf. Reporting helps the FDA monitor post-market safety signals for all testosterone formulations.

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Can testosterone gel cause a skin rash?

Yes. Application-site reactions are reported in approximately 3 to 5 percent of patients in the key AndroGel 1% registration trials. Most are irritant contact dermatitis from the ethanol vehicle, causing redness, itching, or dry skin where the gel is applied. Mild dryness or faint redness in the first week is more common and often fades as the skin adapts.

How can I treat a rash caused by testosterone treatment?

Start with measures that address the cause: rotate application sites, let the gel dry fully before clothing touches it, and apply a fragrance-free ceramide emollient to the site 30 to 60 minutes before the gel. For an active flare, a twice-daily 1% hydrocortisone cream for 5 to 7 days can reduce inflammation. If there is no improvement after 2 weeks of these measures, the next step is patch testing and considering a formulation switch.

Can I put AndroGel on my thighs?

No. The approved AndroGel sites are the right and left upper arms, shoulders, or abdomen, per the prescribing information. Thigh application is the site for Fortesta, a different testosterone gel 2%. Rotating among the approved sites on a fixed schedule reduces ethanol exposure at any single area.

References

Show all 12 referencesHide references
  1. AbbVie Inc. AndroGel (testosterone gel) 1% and 1.62% [Prescribing Information]. FDA. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021449s030lbl.pdf
  2. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. In: StatPearls [Internet]. NIH National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK556130/
  3. Choi EH. Mechanisms of alcohol-induced irritant contact dermatitis. Contact Dermatitis. 2019. https://onlinelibrary.wiley.com/doi/10.1111/cod.13183
  4. Warshaw EM, et al. Patch-test reactions to testosterone and excipients in topical TRT. Contact Dermatitis. 2016. https://onlinelibrary.wiley.com/doi/10.1111/cod.12532
  5. Jacobi U, et al. Ceramide-dominant barrier repair in ethanol-induced ICD. Journal of the American Academy of Dermatology. 2016. https://www.jaad.org/article/S0190-9622(15)02614-0/fulltext
  6. Fowler JF, et al. AAD guidelines of care for contact dermatitis. Journal of the American Academy of Dermatology. 2019. https://www.jaad.org/article/S0190-9622(18)32137-8/fulltext
  7. Wang C, et al. Comparative pharmacokinetics of AndroGel 1% vs 1.62%. Journal of Clinical Endocrinology and Metabolism. 2011. https://academic.oup.com/jcem/article/96/3/726/2597205
  8. Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018. https://academic.oup.com/jcem/article/103/5/1715/4939465
  9. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. CTEP. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
  10. FDA MedWatch. Safety information and adverse event reporting program. U.S. Food and Drug Administration. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
  11. Reddit participants. Testosterone gel… where do you put yours? (r/Menopause). Accessed 2026-11-11.
  12. Reddit participants. switching to androgel: anyone have a "what i wish i knew before i started"? (r/TestosteroneKickoff). Accessed 2026-11-11.
Evidence overview for Managing Skin Irritation on AndroGel (testosterone topical): The HealthRX.com Step-by-Step Protocol